Health ❯ Healthcare ❯ Pharmaceuticals

Weight Loss Drugs

Zepbound Wegovy Mounjaro Ozempic Tirzepatide GLP-1 Receptor Agonists GLP-1 Medications Semaglutide GLP-1 Agonists Clinical Trials GLP-1 Drugs Eli Lilly and Novo Nordisk GLP-1 Injections Novo Nordisk Obesity Treatment Medicare and Medicaid Coverage Ozempic and Wegovy Bimagrumab GLP-1 Therapies Patient Management Mounjaro (Tirzepatide) Hims & Hers Health, Inc. Demand and Supply Issues Eli Lilly's Orforglipron Obesity Treatments Costco Discounts Pricing and Accessibility Prescription Pricing Retatrutid Wegovy and Ozempic Orforglipron Drug Pricing Eli Lilly vs Novo Nordisk Ozempic 2.0 Mounjaro and Zepbound GLP-1 Compounds Eli Lilly Zepbound Compounded Semaglutide Oral Medications Eli Lilly GLP-1 Class GLP-1 Receptor Analogs Compounded Medications CagriSema GLP-1 Treatments Eye Health Medi-Cal Coverage Wegovy and Mounjaro Zepbound vs Wegovy Ozempic and Mounjaro Long-term Effects Ozempic and Tirzepatide

GLP-1 Boom Hits a Crossroads as States Cut Coverage and Next‑Gen Drugs Advance

Budget pressures alongside mixed late-stage data are reshaping access and expectations.

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Eli Lilly Lifts 2025 Guidance After Tirzepatide Fuels Blowout Quarter

Lilly Taps Walmart for First Retail Pickup of Discounted Zepbound Vials Starting Mid-November

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves